Association of TNF2, a TNF-α promoter polymorphism, with septic shock susceptibility and mortality -: A multicenter study

被引:540
作者
Mira, JP
Cariou, A
Grall, F
Delclaux, C
Losser, MR
Heshmati, F
Cheval, C
Monchi, M
Teboul, JL
Riché, F
Leleu, G
Arbibe, L
Mignon, A
Delpech, M
Dhainaut, JF
机构
[1] Cochin Port Royal Univ Hosp, Intens Care Unit, F-75679 Paris, France
[2] Cochin Port Royal Univ Hosp, Lab Biochem Genet, F-75679 Paris 14, France
[3] Lariboisiere Univ Hosp, Intens Care Unit, Paris, France
[4] St Joseph Univ Hosp, Paris, France
[5] Kremlin Bicetre Univ Hosp, Paris, France
[6] St Louis Univ Hosp, Paris, France
[7] Cochin Hosp, Blood Bank, Paris, France
[8] Mondor Univ Hosp, Creteil, France
来源
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 1999年 / 282卷 / 06期
关键词
D O I
10.1001/jama.282.6.561
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context Tumor necrosis factor alpha (TNF-alpha) is believed to be a cytokine central to pathogenesis of septic shock. TNF2, a polymorphism within the TNF-alpha gene pro meter, has been associated with enhanced TNF-alpha production and negative outcome in some severe infections. Objectives To investigate the frequency of the TNF2 allele in patients with septic shock and to determine whether the allele is associated with the occurrence and outcome of septic shock. Design Multicenter case-control study conducted from March 1996 to June 1997, Setting Seven medical intensive care units in university hospitals. Subjects Eighty-nine patients with septic shock and 87 healthy unrelated blood donors. Main Outcome Measures Frequency of the TNF2 allele among patients with septic shock and among those who died and the level of corresponding TNF-alpha concentrations. Results Mortality among patients with septic shock was 54%, consistent with the predicted mortality from the Simplified Acute Physiologic Score (SAPS II) value. The polymorphism frequencies of the controls and the patients with septic shock differed only at the TNF2 allele (39% vs 18% in the septic shock and control groups, respectively, P =.002). Among the septic shock patients, TNF2 polymorphism frequency was significantly greater among those who had died (52% vs 24% in the survival group. P =.008). Concentrations of TNF-alpha were higher in 68% and 52% with the TNF2 and TNF1 polymorphisms, respectively, but their median Values (48 pg/mL vs 29 pg/mL) were not statistically different (P =.31). After controlling for age and the probability of death, derived by the SAPS II score, multiple logistic regression analysis showed that, for the same rank of SAPS ii value, patients with the TNF2 allele had a 3.7-fold risk of death (95% confidence interval, 1.37-20.24). Conclusion The TNF2 allele is strongly associated with susceptibility to septic shock and death due to septic shock.
引用
收藏
页码:561 / 568
页数:8
相关论文
共 50 条
  • [1] EFFICACY AND SAFETY OF MONOCLONAL-ANTIBODY TO HUMAN TUMOR-NECROSIS-FACTOR-ALPHA IN PATIENTS WITH SEPSIS SYNDROME - A RANDOMIZED, CONTROLLED, DOUBLE-BLIND, MULTICENTER CLINICAL-TRIAL
    ABRAHAM, E
    WUNDERINK, R
    SILVERMAN, H
    PERL, TM
    NASRAWAY, S
    LEVY, H
    BONE, R
    WENZEL, RP
    BALK, R
    ALLRED, R
    PENNINGTON, JE
    WHERRY, JC
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 273 (12): : 934 - 941
  • [2] Abraham E, 1998, LANCET, V351, P929
  • [3] Aggarwal BB, 1996, EUR CYTOKINE NETW, V7, P93
  • [4] Acute-phase gene expression correlates with intrahepatic tumor necrosis factor-alpha abundance but not with plasma tumor necrosis factor concentrations during sepsis systemic inflammatory response syndrome in the rat
    Andrejko, KM
    Deutschman, CS
    [J]. CRITICAL CARE MEDICINE, 1996, 24 (12) : 1947 - 1952
  • [5] DIVERGENT EFFICACY OF ANTIBODY TO TUMOR-NECROSIS-FACTOR-ALPHA IN INTRAVASCULAR AND PERITONITIS MODELS OF SEPSIS
    BAGBY, GJ
    PLESSALA, KJ
    WILSON, LA
    THOMPSON, JJ
    NELSON, S
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1991, 163 (01) : 83 - 88
  • [6] AMERICAN-COLLEGE OF CHEST PHYSICIANS SOCIETY OF CRITICAL CARE MEDICINE CONSENSUS CONFERENCE - DEFINITIONS FOR SEPSIS AND ORGAN FAILURE AND GUIDELINES FOR THE USE OF INNOVATIVE THERAPIES IN SEPSIS
    BONE, RC
    BALK, RA
    CERRA, FB
    DELLINGER, RP
    FEIN, AM
    KNAUS, WA
    SCHEIN, RMH
    SIBBALD, WJ
    ABRAMS, JH
    BERNARD, GR
    BIONDI, JW
    CALVIN, JE
    DEMLING, R
    FAHEY, PJ
    FISHER, CJ
    FRANKLIN, C
    GORELICK, KJ
    KELLEY, MA
    MAKI, DG
    MARSHALL, JC
    MERRILL, WW
    PRIBBLE, JP
    RACKOW, EC
    RODELL, TC
    SHEAGREN, JN
    SILVER, M
    SPRUNG, CL
    STRAUBE, RC
    TOBIN, MJ
    TRENHOLME, GM
    WAGNER, DP
    WEBB, CD
    WHERRY, JC
    WIEDEMANN, HP
    WORTEL, CH
    [J]. CRITICAL CARE MEDICINE, 1992, 20 (06) : 864 - 874
  • [7] Why sepsis trials fail
    Bone, RC
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 276 (07): : 565 - 566
  • [8] Secretion of tumour necrosis factor alpha and lymphotoxin alpha in relation to polymorphisms in the TNF genes and HLA-DR alleles. Relevance for inflammatory bowel disease
    Bouma, G
    Crusius, JBA
    Pool, MO
    Kolkman, JJ
    VonBlomberg, BME
    Kostense, PJ
    Giphart, MJ
    Schreuder, GMT
    Meuwissen, SGM
    Pena, AS
    [J]. SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 1996, 43 (04) : 456 - 463
  • [9] POLYMORPHISM IN TUMOR-NECROSIS-FACTOR GENES ASSOCIATED WITH MUCOCUTANEOUS LEISHMANIASIS
    CABRERA, M
    SHAW, MA
    SHARPLES, C
    WILLIAMS, H
    CASTES, M
    CONVIT, J
    BLACKWELL, JM
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1995, 182 (05) : 1259 - 1264
  • [10] PROGNOSTIC VALUES OF TUMOR-NECROSIS-FACTOR CACHECTIN, INTERLEUKIN-1, INTERFERON-ALPHA, AND INTERFERON-GAMMA IN THE SERUM OF PATIENTS WITH SEPTIC SHOCK
    CALANDRA, T
    BAUMGARTNER, JD
    GRAU, GE
    WU, MM
    LAMBERT, PH
    SCHELLEKENS, J
    VERHOEF, J
    GLAUSER, MP
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1990, 161 (05) : 982 - 987